--- title: Atopic dermatitis clinic trial report description: Phesi has published a new report using data from its award-winning AI-powered Trial Accelerator™ platform to analyse phase 3 studies in atopic dermatitis. --- [![New_Phesi_logo_May23](https://info.phesi.com/hs-fs/hubfs/New_Phesi_logo_May23.png?width=250&height=69&name=New_Phesi_logo_May23.png "New_Phesi_logo_May23")](https://www.phesi.com/)   **ATOPIC DERMATITIS REPORT  ** **KEY LEARNINGS FROM PHESI’S ANALYSIS OF PHASE 3 CLINICAL TRIALS**     [Read the report](https://info.phesi.com/hubfs/25_JUN_Atopic%20Dermatitis.pdf?hsLang=en) Phase 3 trials in multiple indications are heading for avoidable failure. Overly complex trial design, coupled with a lack of real-world data integration, is leading to investigator site saturation and increased burden on patients and investigators. To highlight the systemic issues, Phesi has published a new report using data from its award-winning AI-powered Trial Accelerator™ platform to analyse phase 3 studies in atopic dermatitis. A particularly active indication in development currently, atopic dermatitis ranks second after non-small cell lung cancer, with 18 active trials.   See the data and read the report [Read the report](https://info.phesi.com/hubfs/25_JUN_Atopic%20Dermatitis.pdf?hsLang=en) ![Atopic dermititis report cover](https://info.phesi.com/hs-fs/hubfs/Atopic_dermatitis_cover.png?width=300&height=423&name=Atopic_dermatitis_cover.png "Atopic dermititis report cover") ## Get our latest content ![25_JAN_Most_studied_report](https://info.phesi.com/hs-fs/hubfs/25_JAN_Most_studied_report.png?width=177&height=250&name=25_JAN_Most_studied_report.png "25_JAN_Most_studied_report") ![Dig_patient_card](https://info.phesi.com/hs-fs/hubfs/Dig_patient_card.png?width=250&height=250&name=Dig_patient_card.png "Dig_patient_card") ![Nature-card](https://info.phesi.com/hs-fs/hubfs/Nature-card.png?width=250&height=250&name=Nature-card.png "Nature-card") 2024 Most Studied Disease areas Phesi’s annual global analysis of 67,469 recruiting clinical trials shows that breast cancer is the world’s most studied disease for the fourth year running. The data reveals one in three clinical trials were terminated during Phase II, a 50% increase from pre-COVID 19 levels. This represents tens of millions of dollars that could be saved by using data science, AI and clinical data analytics to deliver greater precision in trial design and execution. [Read the report](https://info.phesi.com/24_most_studied?hsLang=en) **Digital Patient Profile Catalogue** Leveraging global data from more than 132 million patients, Trial Accelerator™ generates a detailed picture of the patient for any indication, ensuring greater precision in trial design and execution.         [Download the paper](https://info.phesi.com/dpp-jan24?hsLang=en) **Nature Publication** Read our Nature publication to discover the potential of AI-powered digital twins to replace external control arms in clinical trials.         [Read the report](https://www.phesi.com/news/digital-twin-nature-publication/) ## Book a demo of Trial Accelerator © Phesi Inc. 2025 [mailto:e.casey@phesi.com](mailto:e.casey@phesi.com)